Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazanda for breakthrough cancer pain in the ED
NCT01812759Phase 4Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough cancer pain (BTcP), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2014; status: terminated.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT01812759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01812759.